Close Menu

Biocept

OHSU was granted the rights to offer Biocept's Target Selector liquid biopsy testing services in Oregon as part of the deal. 

The company said it expects to net around $8.4 million, which it will use for working capital and general corporate purposes.

Catalyst will use Biocept's liquid biopsy platform to screen for cancer in patients in a clinical study of its rare disease drug Firdapse.

The company said it accessioned 1,175 total samples during the quarter, up from 663 total samples in Q4 2015.

Ahead of a longer-term goal to develop IVD kits, the company has a plan this year to allow early-access customers to take on one aspect of testing in their own labs.

The firm was able to maintain a minimum closing bid price of at least $1 per share for at least 10 consecutive business days.

Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.

Investigators will compare results using Biocept's platform in cerebrospinal fluid to current standard methods for diagnosing leptomeningeal metastases.

The company said in a filing with the US Securities and Exchange Commission that it failed to maintain compliance with the Nasdaq's minimum closing bid price requirement.

The maker of cancer biomarker assays reported record revenues of more than $1 million in the quarter compared to $164,858 in the prior-year period.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.